NCT01809743 - Regadenoson and Adenosine | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

Coronary Artery Disease

Interventions

DRUG

Regadenoson central -central

To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).

DRUG

Regadenoson peripheral - peripheral

To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).

DRUG

Regadenoson central - peripheral

To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).

DRUG

Regadenoson peripheral - central

To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).

DRUG

Adenosine

Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.

Trial Locations (1)

5623 EJ

Catharina Hospital, Eindhoven